JNJ · News · 20260922N
DePuy Synthes Divestiture
JOHNSON & JOHNSON · 2026-09-22 · Importance 58 · Surprise 42 · In source text
Johnson & Johnson is reportedly considering selling its DePuy Synthes orthopedics unit to Apollo Global Management for approximately $20 billion. The potential divestiture follows J&J’s 2023 Kenvue spinoff and would further streamline the company’s portfolio. Reported strategic rationale includes concentrating on higher-margin, faster-growing pharmaceutical and medical-device businesses and improving profitability.
Key facts
- Johnson & Johnson is reportedly considering selling its DePuy Synthes orthopedics unit to Apollo Global Management for $20 billion. source
- Johnson & Johnson is moving to divest its DePuy Synthes orthopedic division, potentially through a sale to Apollo Global Management for $20 billion. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | contingent | +1.5% | Johnson & Johnson is moving to divest its DePuy Synthes orthopedic division, potentially through a sale to Apollo Global Management for… |
| assets | negative | contingent | — | Johnson & Johnson is moving to divest its DePuy Synthes orthopedic division, potentially through a sale to Apollo Global Management for… |